Cardiac Function under Antiviral TheRapy

Recruiting

• Conditions: B18.2; I50; Chronic viral hepatitis C; Heart failure

• Registration Number: DRKS00020975
• Lead Sponsor: Klinikum Coburg - REGIOMED

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-08-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 97

Inclusion Criteria

HCV positive patients

Exclusion Criteria

HBsAg +, clinically manifested coronary heart disease

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
T-proBNP: before (initial value) and at the end of therapy (follow up - 12 weeks)

Secondary Outcome Measures

Name	Time	Method
echocardiographic measurements (ejection fraction, LVESV, E/A ratio, ..); <br>laboratory measurements: inflammatory markers (CRP, IL6), transaminases (ALT, AST), gGT, AP